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ABSTRACT 
While tumour cells are classically known to communicate via direct cell-to-cell contact and 
the secretion of soluble protein-based factors such as cytokines and growth factors, 
alternative novel mechanisms that promote tumour progression have recently emerged. Now, 
new critical components of the secretome thought to be involved in tumour progression are 
exosomes, small vesicles of endocytic origin that carry a variety of bioactive molecules, 
including proteins, lipids, RNA, as well as DNA molecules. Cancer cell-derived exosomes 
have been shown to participate in crucial steps of metastatic spread of a primary tumour, 
ranging from oncogenic reprogramming of malignant cells to formation of pre-metastatic 
niches. These effects are achieved through the mediation of intercellular cross-talk and 
subsequent modification of both local and distant microenvironments in an autocrine and 
paracrine fashion. Here, we summarise the recent findings that implicate this non-canonical 
signalling within the tumour as a critical driver of metastatic disease progression, and discuss 
how understanding the molecular mechanisms involved in exosome-mediated metastasis is of 
great value for the development of new therapeutic strategies to prevent cancer progression. 
 
INTRODUCTION 
Despite significant advancements in therapies, a large proportion of cancer patients will 
ultimately pass away due to metastatic disease progression. It is therefore a key goal of 
cancer research efforts to further our understanding of metastatic disease progression and its 
dynamics. Based on recent research findings, it is clear that metastatic disease is not a 
random process. That is, the seeding of cancer cells at secondary organs does occur in an 
organ-specific manner, depending on the cancer type, verifying the so called “seed and soil” 
hypothesis, which was originally proposed over 100 years ago by Stephen Paget [1, 2]. This 
concept of metastatic growth specificity has since been validated experimentally and 
clinically [3], and decisively shown that even when cancer cells can be found in the 
vasculature of multiple organs, only selective sites consistently develop metastatic tumour 
deposits [4]. It is now widely accepted that the spread of cancer cells to secondary organs is 
indeed promoted by the prior formation of a specialised environment at distant sites, termed 
the pre-metastatic niche. 
Originally, pre-metastatic niche formation was shown to consist of bone marrow-derived 
hematopoietic progenitor cells (BMDCs), which accumulate at pre-metastatic sites in organs 
different to the site of the primary tumour and before the arrival of any cancer cells [5]. These 
BMDCs expressed VLA-4, and were recruited by tumour-derived and secreted factors, which 
resulted in the accumulation of the VLA-4 ligand fibronectin at pre-metastatic organs [5]. 
Since then, numerous studies have established that variable tumour-secreted factors are 
responsible for establishing a permissive secondary organ through the modulation of a 
number of stromal cell-types [6]. However, these studies have largely focused on canonical 
intercellular communication based on classical cytokines, chemokines and growth factors; 
yet, it is becoming evident non-canonical signalling pathways are also involved in pre-
metastatic niche formation [7]. 
More recently, a new mechanism of intercellular communication via the secretion of 
extracellular vesicles (EVs) has been established as an integral part of complex tumour-host 
interactions [8]. Clinical interest in EVs has heightened due to the fact that continuing 
evidence supports the notion that EVs represent a new paradigm of intercellular 
communication [9]. EVs are constitutively secreted by most likely all different cell lineages 
in the body, and carry diverse molecular contents, including proteins, lipids, RNA (mRNA, 
miRNA, lncRNA, and other RNA molecules), as well as DNA molecules (dsDNA, ssDNA, 
mtDNA) [10]. There are a variety of EVs subtypes, and their accurate annotation is currently 
an ongoing, contentious problem in the field [11]. There are clearly two distinct subtypes of 
EVs that can be separated effectively through differential centrifugation: microvesicles are 
the larger subclass (200 – 1000 nm) and sediment between 10,000 and 20,000 g, while 
smaller EVs known as exosomes exhibit a more homogenous size distribution of 30 – 150 
nm, and sediment at 100,000 g [9, 11, 12]. Exosomes are constitutively released by a variety 
of cell lineages, including cancer cells [10]. The biogenesis of exosomes is classically 
described as originating from the endosomal compartment and are formed as intraluminal 
vesicles by inward budding of the limiting membrane of late endosomes, forming 
multivescular bodies (MVBs). The subsequent fusion of MVBs with the plasma membrane 
allows the release of exosomes into the extracellular environment. This fusion and release 
into the extracellular milieu, allows cancer cells to utilise exosomes to modify local 
microenvironments, or systemically modify distant organs to provide favourable 
microenvironments for the dissemination and outgrowth of metastases [13-15]. These effects 
are achieved by the bioactive molecular constituents of exosomes mentioned earlier, which 
are in turn determined by the cell of origin that the exosomes are secreted from [10, 13-15]. 
For this very reason, exosomes have become a valuable target in identifying novel cancer 
biomarkers that could potentially diagnose cancer, predict patient outcome or response, and 
understand, and perhaps prevent, cancer progression. 
Cancer cell-derived exosomes have been shown to significantly contribute to different 
aspects of metastatic dissemination of a primary tumour, including invasion of the 
surrounding tissues, angiogenesis, modulation of immune responses, and formation of the 
pre-metastatic niche [16]. The roles exosomes have in pre-metastatic niche formation are 
diverse, and range from metabolic reprogramming to recruitment of numerous immune and 
non-immune stromal cells in order to facilitate metastatic outgrowth. The aim of this review 
is to discuss the particular multi-faceted roles of these extracellular particles that impact both 
cancer cell spread from primary to secondary organs, resulting in the outgrowth of 
macroscopic metastatic lesions (Figure 1), and lastly, provide new insights into how this can 
be translated to clinical applications. 
 
THE ROLE OF EXOSOMES IN THE PRIMARY TUMOUR 
MICROENVIRONMENT 
Exosomes and angiogenesis 
A common process known to be involved in tumour progression is hypoxia. Hypoxia is the 
relative reduction in oxygen tension and occurs in all solid tumours larger than 1 cm
3
. This 
results from inadequate blood supply due to the aberrant microcirculation found in most 
tumours [17, 18].
 
The microcirculation is essential in normal tissues homeostasis, as it is 
responsible for balancing the supply of nutrients and removal of cellular waste products [19, 
20]. In the context of a solid tumour, neo-angiogenesis, or the physiological process of new 
blood vessel growth, is necessary for continued tumour growth in response to hypoxia [19, 
20]. Typically, solid tumours have been described to induce vascular remodelling through the 
secretion of soluble factors, such as VEGF and PIGF. However, exosomes are also capable of 
being key mediators between cancer cells and the surrounding vasculature by eliciting pro-
angiogenic responses [21, 22]. Hypoxic glioblastoma-derived exosomes are capable of 
inducing microvasculature sprouting and vascularisation of xenografts models [22]. In 
response to this angiogenic phenotype, tumours displayed accelerated growth kinetics, 
demonstrating a role for exosomes during early tumour progression events. Hypoxia content 
changes in multiple myeloma derived exosomes also induce angiogenesis in recipient 
endothelial cells [23]. Under hypoxia conditions, multiple myeloma cells increase the 
secretion of miR-135b contained within exosomes in order to promote an angiogenic 
response. Endothelial cells that received miR-135b-containing exosomes had significantly 
increased HIF-1 alpha levels, as miR-135b binds the 3ʹ-UTR of factor-inhibiting hypoxia-
inducible factor-1 (FIH-1). This induces a hypoxic response and greatly accelerated 
angiogenesis [23].  In further support of the role that exosomes play during angiogenesis, 
CD105
+
 vesicles from renal carcinoma cells have been shown to induce proliferation of 
HUVECs in vitro and in vivo [21]. These data provide novel insights into mechanisms of how 
tumours can circumvent the clinical inhibition of angiogenic proteins (for example through 
VEGF-neutralizing antibodies), and induce vascular remodelling, allowing tumour-induced 
neo-angiogenesis through exosomal transfer. 
Oncogenic transfer 
Tumours typically consist of numerous subclones that are genetically and phenotypically 
different from one another [24]. It is therefore possible that different subclones can transfer 
oncogenic traits via exosomes to other cancer cells in the primary tumour microenvironment. 
Indeed, glioma cells have been shown to enhance tumourigenesis of recipient cells through 
the transfer of mutant epidermal growth factor receptor (EGFRvIII) [25]. Recipient cells were 
then shown to have a higher proliferation index and were more resistant to apoptosis. Mutant 
KRAS can also be transferred via exosomes and increases the three-dimensional growth of 
wild-type recipient colon cells [26]. Furthermore, metastatic melanoma-derived exosomes are 
capable of inducing a metastatic phenotype of non-metastatic melanoma recipient cells [27]. 
It remains unclear whether this protein inheritance changes tumour growth and metastasis in 
a permanent or an acute manner, yet it provides interesting insights into how tumour cells can 
communicate and promote tumour progression through exosomal transfer of oncogenic 
proteins. 
Exosomes and immune suppression 
Rudolf Virchow was the first to observe leukocyte infiltration into tumours in the 19th 
century [28]. Since then, experimental and clinical investigations have demonstrated the close 
association between inflammation and tumourigenesis [29, 30]. However, inflammation can 
have paradoxical roles during tumour progression, the outcome depending on the balance 
between tumour-promoting and tumour-suppressing activities in the local microenvironment 
[30]. Classically, chemokines and cytokines secreted through canonical pathways have been 
thought of as the master regulators of inflammatory processes in the tumour 
microenvironment, yet it has recently emerged that exosomes add another layer of 
complexity to cancer-associated inflammatory reactions. Cancer cell-derived exosomes 
contain molecular constituents that can induce immune cell dysfunction and contribute to 
silencing of anti-tumour immune responses by several different ways [31], either by directly 
altering immune cell function, or indirectly through modifying non-immune cell stromal 
phenotypes. 
Tumour-derived exosomes can suppress T cell immunity and direct immune cells towards a 
tumour-promoting phenotype. The effects on T cells are partly achieved through causing 
apoptosis of cytotoxic T-cells via the transfer of the death ligands FasL and TRAIL [32, 33]. 
Furthermore, exosomes are capable of editing the immune composition of the primary 
tumour microenvironment by recruiting and expanding myeloid-derived suppressor cells 
(MDSCs). These cells have been identified in both humans and mice as a heterogeneous 
population of immature myeloid cells, capable of mediating immunosuppressive functions 
within the tumour microenvironment [34]. In mice, MDSC subsets are characterised by the 
expression of CD11b and Gr-1, while in humans they are usually identified by a 
CD11b
+
/CD33
+
/HLA-DR- phenotype [34]. Breast carcinoma-derived exosomes containing 
prostaglandin E2 and TGF-β skew the development of myeloid cells toward a MDSC 
phenotype, thus promoting tumour development [35]. Whether these and other 
cytokines/chemokines are indeed contained in tumour-derived exosomes or are merely 
contaminants from either tumour or non-tumour cell sources, caused by the exosome 
isolation procedure, is however still a matter of debate [36]. Nonetheless, these data 
collectively suggest that exosomes play a key role in deciding the tumour-promoting fate of 
infiltrating immune cells.  
Tumour-derived exosomes can further promote an immune-suppressed tumour 
microenvironment through the expansion of CD4
+
/CD25
+
 regulatory T cells [37]. This is 
mechanistically linked to the functional expression of CD39 and CD73 on exosomes, and 
consequent ATP-dependent adenosine production in recipient cells [38]. Melanoma 
exosomes also impair dendritic cell (DC) differentiation from monocytes, and simultaneously 
convert these cells toward an immune-suppressive phenotype [39]. In support of these 
observations, an increased frequency of CD14
+
/HLA-DR
-
 myeloid cells associated with a 
TGF--mediated inhibitory activity on T cells was found in the peripheral blood of 
melanoma patients [39]. Even though these studies have focused on the role of immune cell 
uptake in the primary tumour microenvironment, it is interesting to speculate that similar 
mechanisms could be happening at pre-metastatic organs. 
Finally, it seems that modulation of immune cells behaviour by cancer-derived exosomes can 
also be triggered by other mechanisms, such as transfer of functional mRNA between tumour 
and host cells [40]. Transplanting glioma and lung carcinoma cells, engineered to express Cre 
recombinase, into mice with a Cre-lox background, the uptake of Cre mRNA-contaning 
exosomes by CD11b
+
Gr-1
+
 MDSCs present in the primary tumour microenvironment could 
be tracked [40]. It is noteworthy that recombined MDSCs showed alterations in both their 
immunosuppressive phenotype and miRNA profile [40]. These observations suggest a long-
term, stable genetic reprogramming of myeloid cells by exosomes.  
 
EXOSOME-RELATED PRO-METASTATIC MECHANISMS 
In earlier studies, the majority of cancer research has focused on the pathogenesis of the 
primary tumour. However, metastatic disease is responsible for over 90% of cancer-related 
deaths, and very few therapies have proven successful in the clinic for treating patients with 
metastatic deposits [41]. Therefore, we need to understand the underlying mechanisms of 
metastasis in order to generate novel, effective therapies for patients with advanced, 
aggressive cancers. The metastatic process is composed of a number of sequential events that 
tumour cells are required to accomplish in order to successfully disseminate to secondary 
organs. Known as the metastatic cascade, a series of steps involving local invasion, survival 
and evasion of immune responses, intravasation into the circulation, and extravasation at 
secondary organs are required for the formation of macroscopic metastatic lesions. 
Importantly, exosomes are capable of enhancing the systematic entry and progression of 
cancer cells along the metastatic cascade [19, 20], highlighting the importance of 
understanding exosome biology in metastatic disease progression. In the following 
paragraphs, we will further examine the role of cancer-derived exosomes in diverse 
mechanisms relating to metastasis, which can orchestrate pre-metastatic niche establishment 
at secondary organs and consequent metastatic outgrowth (Figure 1). 
The role of tumour-exosomes in pre-metastatic niche formation 
Changes at secondary organs prior to tumour cell metastasis were first described to be caused 
by matrix metalloproteinase 9 (MMP-9), which is specifically induced in pre-metastatic lung 
endothelial cells and macrophages by distant primary tumour cells [42]. The term „pre-
metastatic niche‟ was coined later by demonstrating that tumour-derived conditioned media 
alone is capable of inducing migration of VEGFR-1-expressing BMDCs into organ-specific 
pre-metastatic sites, as well as posterior formation of BMDCs clusters that precede tumour 
cell arrival [5]. These clusters, in turn, create a favourable microenvironment for incoming 
tumour cells, in a mechanism dependent on the expression of fibronectin, VLA-4, Id3, and 
MMP-9 [5]. Cell-free conditioned medium from hypoxic breast cancers was also shown to 
drive the accumulation of a specific subset of BMDCs, known as CD11b
+
 MDSCs, in the 
lungs of immune-competent mice [43]. There, the formation of an immune suppressed 
environment through the reduced cytotoxic capacity of Natural Killer (NK) cells, in turn 
promote the metastatic outgrowth of both breast cancer and melanoma tumours [43]. Since 
then, a variety of BMDC lineages, among other organ resident cell lineages, have been shown 
to contribute to the generation of pre-metastatic niches, and a large number of chemokines, 
cytokines and growth factors have been connected to specific pre-metastatic niche-related 
processes [44, 45]. In recent times, exosomes have been described to have unique and central 
functions during pre-metastatic niche establishment and maintenance. 
Exosomes and vascular remodelling in pre-metastatic niches 
Modulation of vascular permeability, and stimulation of neo-angiogenesis, are key steps 
during pre-metastatic niche establishment that favour the initial extravasation and subsequent 
metastatic growth of tumour cells into secondary organs [45]. The ability to modulate 
endothelial cell activity could also represent a crucial element in the repertoire of pro-
metastatic roles of tumour-derived exosomes. Recently, the importance of extracellular 
miRNA contained within exosomes in vascular remodelling has been highlighted. Metastatic 
MDA-MB-231 breast cancer cells secrete exosomes enriched for the miRNA miR-105 [46]. 
The presence of this miRNA in breast cancer-derived exosomes increases metastasis by 
facilitating endothelial cell barrier destruction through down-regulation of the tight junction 
zonula occludens 1 (ZO-1) protein. The reduction of ZO-1 by miR-105 increases endothelial 
barrier permeability and facilitates cancer cell migration in vitro and in vivo. Perturbation of 
vascular cell barrier function is a key step in allowing cancer cells to not only intravasate into 
the circulation, but also extravasate at secondary sites to form metastatic lesions. Indeed, 
exosomal miR-105 increased vascular permeability at secondary organs, thereby increasing 
metastasis by facilitating colonisation of new tissues [46]. 
In support of these observations, exosomes purified from the supernatant of CD105+ renal 
cancer stem cells that induced vascular remodelling by increasing angiogenesis at the primary 
tumour, also induced an angiogenic response at pre-metastatic sites [21]. CD105
+
 vesicles 
enhance lung metastasis in vivo due to the uptake and parallel up-regulation of VEGF and 
MMP-2 in lung endothelial cells [21], thereby demonstrating the importance of vascular 
remodelling at pre-metastatic organs. Melanoma-derived exosomes also accumulated at 
common sites of melanoma metastasis, and subsequently caused vascular remodelling by 
enhancing endothelial cell permeability and up-regulation of the expression of many genes 
previously associated with a microenvironment conducive to metastatic outgrowth [15].  
Taken together, these results demonstrate that tumour exosomes exhibit a strong impact on 
endothelial cell function, which could contribute to remodelling of the microenvironment in 
order to promote tumour progression. It is noteworthy, however, that induction of vascular 
permeability by tumour exosomes in distant organs, such as the lung, is not always 
accompanied by lung parenchyma uptake or facilitation of metastasis [14]. These 
observations indicate that vascular remodelling alone is not sufficient to promote tumour 
outgrowth in secondary organs, although it is regarded as a necessary step during the 
metastatic cascade. 
Effects of cancer-derived exosomes on other non-immune cells 
Apart from endothelium modifications, tumour-derived exosomes may be capable of altering 
the metastatic niche by directly targeting other non-immune stromal cells, including 
mesenchymal stem cells, fibroblasts and epithelial cells and, in this way, promote tumour-
supportive processes through extracellular matrix (ECM) remodelling and induction of 
angiogenesis. For example, exosomes produced by human chronic lymphocytic leukemia 
cells were shown to be taken up by mesenchymal stem cells in vitro [47]. As a result, the cell 
proliferation of the recipient cells is increased, as is their migration and adhesion to tumour 
cells [47]. In addition, these recipient mesenchymal stem cells are associated with enhanced 
secretion of inflammatory cytokines that seemed to contribute to tumour cell survival [47]. In 
fact, TGF--containing exosomes obtained from various cancer cell lines (including 
mesothelioma, prostate and gastric cancer cells) can drive distinct changes in primary 
fibroblasts and mesenchymal stem cells consistent with their differentiation into a 
myofibroblast-like phenotype [48, 49]. This includes high production of FGF2, VEGF, HGF 
and MMPs, and acquisition of both pro-angiogenic and tumour-promoting characteristics [50, 
51]. The cellular release of soluble factors, such as IL-6 by cholangiocarcinoma-derived 
exosome-treated BM mesenchymal stem cells, also altered tumour cell proliferation, which 
was partially dependent on IL-6R activation [52]. Finally, EMMPRIN, an integral membrane 
protein shed on lung carcinoma-derived exosomes, was found to stimulate the production of 
MMPs by fibroblasts, outlining another mechanism of tumour-stromal cell interaction that 
could influence ECM remodelling in the tumour microenvironment [53]. 
Recently tumour exosomal small RNA has been demonstrated to be required for neutrophil 
recruitment to the pre-metastatic niche after activating resident epithelial cells [54]. This 
neutrophil recruitment is mediated by the expression of toll like receptor (TLR) 3 in alveolar 
type II lung epithelial cells. Small RNA species contained within exosomes stimulate 
activation of TLR3 in lung epithelial cells, thereby increasing chemokine production 
(CXCL1, CXCL2, CXCL5, and CXCL12) and neutrophil recruitment to pre-metastatic sites. 
Neutrophil recruitment has been shown to be involved in cancer metastasis [55, 56]. 
Subsequently, neutrophil recruitment initiates pro-metastatic inflammation and is related to 
the expression of the key metastatic molecules S100A8 and S100A9 [54]. This 
reprogramming of the pre-metastatic niche by small RNAs in exosomes is conducive to 
metastatic invasion and colonisation of secondary organs. These interactions of tumour-
derived exosomes with pre-metastatic niche cells, which in turn recruit BMDCs indicates that 
pre-metastatic niche formation is not simply a binary process, but rather a complicated 
orchestration of signalling involving numerous cells. 
Impact of cancer-derived exosomes on immune cells in pre-metastatic niches 
Among all the BMDCs subsets, CD11b
+
 MDSCs are the most commonly associated with 
tumour progression and pre-metastatic niche generation. Exosomes isolated from different 
types of tumour cells (including breast cancer [35, 57-59], melanoma [58], thymoma [59], 
colon carcinoma [59] and multiple myeloma [60]) have been shown to modulate BMDCs 
behaviour, by either directly skewing their differentiation into MDSCs (as aforementioned) or 
affecting BMDCs homing to pre-metastatic sites.
 
Exosomes derived from breast cancer cells were shown to be preferentially taken up by 
CD11b
+
Gr-1
+
 BMDCs, which in turn accumulated in the spleen and lung of exosome-treated 
mice [57]. Further in vitro assays demonstrated that exosomes impair the differentiation of 
GM-CSF-stimulated BM precursor cells into DCs, as well as their maturation, which is 
partially dependent on exosome-induced IL-6 production [57]. A crucial role for the MyD88-
TLR signalling pathway in MDSCs activation has also been evaluated [58]. After treatment 
with tumour exosomes, MyD88 knockout mice displayed a less prominent accumulation of 
MDSCs in pre-metastatic lung and liver tissues when compared to wild-type animals [58]. 
This was associated with reduced tumour exosome-promoted lung metastasis, as well as with 
decreased TNF-a and IL-6 levels in the serum, and low CCL2 production in the lung [58]. 
Mechanistically, it seems that the heat shock protein HSP70 is involved in tumour exosome-
mediated MDSCs induction in secondary organs, possibly by triggering p-Stat3 in MDSCs in 
a TLR2-MyD88-dependent manner [61]. 
More recently, we have shown the tissue-specific immune-suppressive effects of exosomes 
derived from breast cancer cells with differing metastatic potential [62]. Fluorescently-
labelled tumour exosomes injected into syngeneic mice accumulated predominantly in the 
lung and were preferentially taken up by CD11b
+
 BMDCs, DCs and macrophages, regardless 
of the metastatic phenotype of the cell of origin. Nevertheless, conditioning of tumour naïve 
animals with exosomes derived from highly metastatic breast cancer cells induced a 
significant recruitment of MDSCs to lung and liver compared to non-metastatic isogenic 
exosomes, which was accompanied by a reduced frequency of NK cells [62]. The formation 
of this immune-suppressed microenvironment was then associated with a higher metastatic 
burden in both secondary organs, highlighting that metastatic cancers are highly efficient at 
preparing a permissive microenvironment that enhances metastatic disease progression [62]. 
Strikingly, exosome uptake by BMDCs appears to permanently alter cellular phenotype. This 
alteration was shown with a reconstitution experiment of lethally irradiated control mice with 
stem cells from exosome-treated mice that resulted in a significant increase in the number and 
size of melanoma metastases, as well as in the number of metastasis-associated BMDCs [15]. 
A more detailed assessment of the composition of the bone marrow after reconstitution 
showed an elevated frequency of pro-angiogenic c-kit
+
Tie2
+
 cells after exosome conditioning 
[15]. Compared to exosomes derived from poorly metastatic melanoma cells, exosomes from 
highly metastatic cell lines expressed higher levels of metastasis-related proteins, including 
the MET tyrosine kinase receptor. The transfer of MET was implicated in the pro-metastatic 
changes of bone marrow progenitors, given the key role of MET signalling in migration, and 
angiogenesis [63].  
Selective in vivo uptake of pancreatic cancer exosomes by Kupffer cells was also shown to 
play a key role in liver pre-metastatic niche formation [13]. Kupffer are specialised 
macrophages localised to the liver, and the transfer of macrophage inhibitory factor (MIF) 
from tumour-derived exosomes to these hepatic cells promoted TFG-β production. This 
generated a fibrotic microenvironment through increased fibronectin expression from hepatic 
stellate cells, as well as further arrest of BM-derived macrophages and neutrophils in the 
liver. These myriad changes ultimately enhanced metastatic burden, providing key insights 
into pancreatic cancer liver metastasis [13].  
Additional studies are required to further our understanding of the effects of tumour 
exosomes on immune cells functions, as well as their exact contribution to pre-metastatic 
niche formation. However, these findings collectively indicate that tumour-derived exosomes 
promote metastasis by conditioning the BMDCs phenotype and/or directly interact with 
immune cell lineages present in the pre-metastatic niche. However, some questions still 
remain to be addressed such as: (1) if similar observations can be extended to all types of 
cancer; (2) which immune cell populations are precisely affected by which subsets of 
circulating exosomes after their target to different organs; (3) the alterations in tissue-specific 
immune composition induced by cancer exosome accumulation; (4) which exosomal content 
is responsible for driving the opposing effects on anti-cancer immune regulation; and (5) the 
consequences of exosomal content on immune surveillance during metastatic dissemination. 
In this way, expanding our knowledge about how exosomes impact immune cells to alter 
their function and induce a tumour-supportive environment may improve the efficacy of 
current cancer immunotherapeutics, a highly promising novel class of treatment. 
Modification of the metabolic environment 
In a somewhat unique aspect of pre-metastatic niche biology, exosomal miRNA has also been 
demonstrated to reprogram the metabolic environment of the pre-metastatic niche. 
Circulating miR-122 has been associated with metastasis in breast cancer patients [64]. 
Interestingly overexpression of miR-122 in an experimental breast cancer model reduced 
primary tumour growth, yet enhanced metastasis [65]. miR-122 is contained within breast 
cancer-derived exosomes and taken up by recipient cells in the pre-metastatic niche of the 
brain and the lung in vivo [65]. Uptake of miR-122 by recipient cells specifically reduces 
pyruvate kinase (PKM) expression, and results in decreased GLUT1 and glucose uptake. 
When miR-122 containing exosomes were injected into mice, the expression of PKM and 
GLUT1 in the brain, and the lung was reduced. Metabolic reprogramming of the pre-
metastatic niche enhanced metastasis, presumably due to the increased nutrient availability 
for arriving tumour cells. Cancer cells typically have a high energy demand, and this unique 
line of investigation demonstrates that cancer cells can systemically suppress nutrient 
utilisation of residing cells in secondary organs in order to favour incoming cancer cells. 
Determination of organotropic homing 
Organotropic homing of cancer cells to specific organs is of significant importance in 
metastatic research. This phenomenon has largely been demonstrated with tumour-derived 
soluble factors. That is, mice treated with melanoma-derived conditioned medium redirected 
metastatic outgrowth of lung carcinoma cells to sites typical of melanoma but not lung cancer 
metastasis [5]. This suggested that tumour-derived factors could be capable of inducing 
organotropic specific homing. In this context, exosomes have been recently identified as 
drivers of organotropic metastatic spread, through preferential accumulation at future 
metastatic sites. This was first established with melanoma-derived exosomes which 
accumulated in sentinel lymph nodes, whereas control liposomes (man-made lipid-based 
nanoparticles) evenly spread to regional and distant nodes [66]. Exosome localisation to these 
sites was accompanied by several modifications in the microenvironment, such as matrix 
deposition and vascular proliferation, and thereby facilitated lymphatic melanoma metastasis, 
implicating exosomes in not only pre-metastatic niche formation, but specific organotropic 
modulation [66]. Organotropism of exosomes is supported by the assessment of the 
biodistribution and molecular profiles of exosomes obtained from several cancer cells with 
distinct organotropism [14]. Exosomes accumulate in different tissues, however, exosome 
localisation recapitulated the organ-specificity of secreting cells [14]. More strikingly, 
exosomes obtained from lung-tropic breast cancer cells could promote the dissemination of a 
bone-tropic cancer-cell population into the lung, demonstrating their ability to redirecting 
metastatic spread of tumour cells [14].  
The organotropic nature of exosomes is largely attributed to a specific repertoire of exosomal 
surface integrins that was found to dictate exosome homing to distant organs, as well as 
uptake by distinct target cells, thereby promoting a favourable pre-metastatic niche [14]. For 
instance, α6β4- and α6β1-expressing exosomes preferentially interacted with fibroblasts and 
epithelial cells in the lung, whereas αvβ5 integrin-enriched exosomes were preferentially 
taken up by Kupffer cells within the liver microenvironment [14]. Perhaps most interesting 
was the finding that integrins β4 and αv expression in exosomes isolated from the plasma of 
cancer patients could predict metastasis to lung and liver, respectively. Interestingly, this 
finding suggests that circulating tumour-derived exosomes can be utilised as biomarkers to 
determine organotropic metastatic outgrowth [14]. While this work greatly extends our 
understanding of the molecular mechanisms involved in organ-specific metastasis and 
corroborated the role of exosomes on the formation of pre-metastatic niche as well as on 
tumour progression, it also raised several questions. Bone-tropic exosomes, for example, 
were unable to redirect lung-tropic cell metastasis, and also displayed a limited integrin 
repertoire [14]. Thus, integrin profiles alone are unlikely to account for the promotion of 
organotropic metastasis in all types of cancer, suggesting that additional organ-specific traits 
of exosomes will still need to be defined. Given these data, it is apparent further investigation 
is required to determine how these achievements can be translated to the clinical management 
of cancer patients, especially on the use of exosomal molecular profiles in both cancer 
diagnostics and therapeutics. 
Non-tumour-derived exosomes 
Tumour-derived exosomes are certainly capable of promoting metastasis, however it is also 
apparent that autocrine and paracrine signalling at secondary microenvironments – 
independent of cancer cells – are integral in the metastatic seeding and outgrowth of cancer 
cells [67]. Recently, exosomes derived from cells residing at secondary microenvironments 
have been shown to be essential for metastatic outgrowth after extravasation [67]. In 
particular, astrocyte-derived exosomes were shown to be responsible for inducing PTEN loss 
in brain metastases. PTEN loss was induced by astrocyte-derived exosomal miR-19a, and 
was essential for metastatic outgrowth in the brain due to the reciprocal secretion of CCL2 
and recruitment of IBA1-expressing myeloid cells. This specific response to the 
microenvironment of the brain enhanced cancer cell proliferation and reduced apoptosis, 
highlighting the importance of understanding not only tumour-derived exosomes, but also 
exosomes derived from other cell types at secondary organs. 
CLINICAL UTILITY OF EXOSOMES 
The evident and rapid emergence of numerous publications on extracellular vesicles has 
highlighted the importance of these extracellular components as biomarkers of disease, 
particularly cancer. There is currently a large unmet clinical need to develop minimally-
invasive prognostic or diagnostic markers for most cancer types. Given that exosomes 
contain a myriad of novel proteomic and RNA biomarkers [68, 69], which have important 
functions, particularly in metastatic dissemination and pre-metastatic niche formation, 
tumour-derived exosomes are being touted as the next significant advancement in the 
biomarker quest [69]. However, there are still several hurdles to overcome for retrospective 
and prospective clinical investigations. Technical standardisation is of the upmost importance 
for utilising exosome biomarkers [70]. We have previously demonstrated that different 
isolation protocols will deliver significantly different purities, and therefore, contain various 
abundances of non-exosomal contaminants that may confound subsequent analysis [12]. 
Given the disparate isolation techniques currently being employed worldwide, a complete 
standardisation of isolation techniques is critical, particularly in order to reproduce 
retrospective trials, and of course, prospective clinical trials, to confirm the validity of the 
putative exosome-based biomarker. 
Even given these limitations, we are at an exciting stage of biomarker discovery utilising 
exosomes. We have discussed the integral role exosomes serve in tumour progression at the 
primary tumour, but also how exosomes are capable of enhancing metastasis and numerous 
steps of the metastatic cascade. Exosomes are capable of these feats through the specific 
RNA and protein content they carry, and we are now in a unique position to hijack the 
information carried by exosomes in order to understand, and perhaps interfere with their 
“intended” purposes, to improve patient outcome through diagnostic measures and superior 
clinical management. 
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FIGURE LEGEND 
Figure 1. Exosomal mechanisms of metastasis promotion. (a) Exosomes secreted by 
cancer cells contribute to the intercellular cross-talk and subsequent reprogramming of the 
primary tumour microenvironment in an autocrine and paracrine fashion. Bioactive content of 
exosomes have been implicated in different aspects of primary tumour progression, including 
angiogenesis, modulation of immune responses, and oncogenic reprogramming. (b) 
Moreover, exosomal factors are capable of mobilising bone marrow-derived cells to the 
primary tumour, which in turn facilitate the establishment of a supportive microenvironment. 
(c) This non-canonical signalling within the primary tumour has also emerged as a critical 
driver of pre-metastatic niche formation. Tumour-derived exosomes can home to specific 
secondary organs and directly modify the local microenvironment by interacting with distinct 
resident cell populations. A variety of factors contained within exosomes were shown to 
participate in a range of biological processes, from modulation of immune and non-immune 
stromal cells to metabolic reprogramming. (d) Chemokines and other pro-inflammatory 
molecules are also upregulated in pre-metastatic sites in response to exosome-mediated 
signalling, leading to the recruitment and activation of bone marrow-derived cells. 
Altogether, exosome-induced pre-metastatic niche modifications generate a 
microenvironment conducive to metastatic outgrowth (e), thereby facilitating cancer cell 
dissemination and colonisation of distant tissues in an organotropic specific manner. 
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